SPRINT: Pill burden affects ability to reach systolic BP control
October 1, 2018
CHICAGO – Patients in the SPRINT trial were less likely to meet the intensive treatment goal – systolic blood pressure below 120 mm Hg – if they were taking five or more medications a day.
Impaired kidney function no problem for dabigatran reversal
April 23, 2018
ORLANDO – Idarucizumab, reversal agent for the anticoagulant dabigatran, worked fine in patients with renal dysfunction.
Common infections are potent risk factor for MI, stroke
April 13, 2018
ORLANDO – Huge U.K. registry identifies a novel cardiovascular risk factor: hospitalization for UTI or respiratory infection.
Post-ACS death lowered in ODYSSEY Outcomes
March 10, 2018
ORLANDO – Mortality and major adverse cardiovascular events were cut 15%, but that’s not all.
Benefit of dabigatran over warfarin persists in AF patient subgroups undergoing PCI
December 3, 2017
ANAHEIM, CALIF. – Dabigatran protected against thromboembolic events with less bleeding regardless of stent type, type of concomitant treatment, or indication for PCI.